TBPMF News and Press, Tetra Bio-Pharma Inc From 05/11/20

OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that its Chief Operating Officer Steeve Néron participated in an interview on Sat...

No adverse events observed in study participants Health Canada VDD grants trial renewal OTTAWA, ON / ACCESSWIRE / May 11, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF) , a leader in cannabinoid-derived drug discovery and development, is pleased t...

OTTAWA, ON / ACCESSWIRE / May 8, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has engaged energi PR Inc. as its public relations firm, led by CEO, Carol Levi...

Phoenix, Arizona--(Newsfile Corp. - May 7, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (OTCQB: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aim...

OTTAWA, ON / ACCESSWIRE / May 6, 2020 / Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has now completed the modifications to the nonclinical safety program of PPP0...

Une preuve de concept pré-clinique du PPP003 a déjà démontré un potentiel pour l'état septique Tetra développera le PPP003 comme thérapie potentielle dans la bataille contre la COVID-19 OTTAWA / ACCESSWIRE / April 27, 2020 / Tetra Bio-Pharma I...

Preclinical proof of concept of PPP003 as potential drug candidate for sepsis demonstrated Tetra to develop PPP003 as potential drug therapy for the battle against COVID-19 OTTAWA, ON / ACCESSWIRE / April 27, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP)(OTCQB...

Phoenix, Arizona--(Newsfile Corp. - April 22, 2020) - The Stock Day Podcast welcomed Tetra Bio-Pharma (OTCQB: TBPMF) ("the Company"), a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program ai...

Tetra targeted ODD applications for ophthalmic, cancer and skin rare diseases Tetra receives its 5th Orphan Drug Designation (ODD) OTTAWA / ACCESSWIRE / April 22, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSXV:TBP)(OTCQB:TBPMF), a leader in cannabinoid-derived drug...

Tetra's PPP004 cannabinoid drug receives Orphan Drug Designation for the Treatment of Epidermolysis Bullosa OTTAWA / ACCESSWIRE / April 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP);(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is...